Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2010 Sep;105(9):1660-8.
doi: 10.1111/j.1360-0443.2010.03020.x.

Failure to improve cigarette smoking abstinence with transdermal selegiline + cognitive behavior therapy

Joel D Killen  1 , Stephen P Fortmann, Greer M Murphy Jr, Chris Hayward, Dalea Fong, Kimberly Lowenthal, Susan W Bryson, Diana T Killen, Alan F Schatzberg
Affiliations
Randomized Controlled Trial

Failure to improve cigarette smoking abstinence with transdermal selegiline + cognitive behavior therapy

Joel D Killen et al. Addiction. 2010 Sep.

Abstract

Aims: To examine the effectiveness of transdermal selegiline for producing cigarette smoking abstinence.

Design: Adult smokers were randomly assigned to receive selegiline transdermal system (STS) or placebo given for 8 weeks. All participants received cognitive behavior therapy (CBT). Follow-ups were conducted at 25 and 52 weeks.

Setting: Community smoking cessation clinic.

Participants: 243 adult smokers (> or =18 years of age; > or =10 cigarettes/day).

Measures: Expired-air carbon monoxide confirmed 7-day point prevalence abstinence.

Findings: STS was not superior to placebo. More women than men were abstinent at 52 week follow-up (28% vs 16%, P < 0.05). Behavioral activation (BAS) moderated treatment response (P = 0.01). The survival rate through week 52 for those with high 'drive' scores on the BAS was 47% if assigned to selegiline and 34% if assigned to placebo. The survival rate for those with low 'drive scores' on the BAS was 35% if assigned to selegiline compared to 53% if assigned to placebo.

Conclusion: Transdermal selegiline does not appear generally effective in aiding smoking cessation though there may be a selective effect in those smokers with low 'behavioral activation'.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow Chart Showing Attrition of Smokers Over 52 Weeks
Figure 2
Figure 2
Survival Curve for BAS Drive by Treatment Group
See this image and copyright information in PMC

References

    1. Killen JD, Fortmann SP. Craving is associated with smoking relapse: Findings from three prospective studies. Exp Clin Psychopharm. 1997;5:137–142. - PubMed
    1. Shiffman S. The tobacco withdrawal syndrome. In: Krasnegor NA, editor. Cigarette smoking as a dependence process. NIDA Res Mon. Vol. 23. Washington, DC: DHEW; 1979. pp. 158–184.
    1. West RJ, Schneider N. Craving for cigarettes. Brit J Addict. 1987;82:407–415. - PubMed
    1. Hafeley W. Biological basis of drug-induced tolerance, rebound, and dependence. Contribution of recent research on benzodiazepines. Pharmacopsychiat. 1986;19:353–361. - PubMed
    1. Koob GF. Drug addiction: The Yin and Yang of hedonic homeostasis. Neuron. 1996;16:893–896. - PubMed

Publication types

MeSH terms